<DOC>
	<DOCNO>NCT01101659</DOCNO>
	<brief_summary>The objective study investigate whether JNJ-40411813 versus placebo reduce psychosis-like symptom , induced infusion low dose ketamine . Effects JNJ-40411813 ketamine-induced symptom evaluate 3 hour single oral dose concentration JNJ-40411813 blood maximum 24 hour dose administration ass duration potential JNJ-40411813 effect .</brief_summary>
	<brief_title>Ketamine Challenge Study With JNJ-40411813</brief_title>
	<detailed_description>This double-blind ( neither physician volunteer knowns whether placebo active drug administer ) , placebo-controlled , randomize ( study drug assign chance ) , 2-way crossover ( procedure repeat twice volunteer receives placebo well active drug ) study cohort maximum 16 healthy male volunteer , investigate effect JNJ 40411813 placebo ketamine-induced psychosis-like symptom . In first cohort ( Cohort 1 ) , JNJ 40411813 effect dose level 500 mg evaluate time maximal plasma concentration . If JNJ 40411813 significantly reduce psychotic symptom relative placebo , second cohort ( Cohort 2 ) initiate investigate effect JNJ 40411813 24 hour follow dose administration . If Cohort 1 show relevant effect JNJ 40411813 study stop . If relevant effect JNJ 40411813 psychotic symptom 24 hour dose , third cohort ( Cohort 3 ) initiate investigate effect 12 hour dose . If relevant effect JNJ 40411813 24 hour dose , fourth cohort ( Cohort 4 ) follow procedure Cohort 1 , initiate investigate effect peak plasma concentration use low dose JNJ 40411813 . Volunteers randomly assign crossover procedure one two sequence ( JNJ 40411813/placebo placebo/ JNJ 40411813 ) Day -1 first study period cohort . At peak plasma level ( Cohorts 1 4 ) , 24 hour ( Cohort 2 ) 12 hour ( Cohort 3 ) dose volunteer receive ketamine infusion ( i.e . directly vein ) 60 minute . The ketamine administration precede saline infusion 90 minute . Tests psychological function volunteer perform saline ketamine infusion . Safety assessment include daily ECG vital sign , clinical laboratory assessment start end study period , pulse oximetry ( measurement oxygen content blood ) ketamine infusion continuous Adverse Event Reporting . The study double blind oral JNJ-40411813 placebo , open label ( everyone know identity ) IV administration saline ketamine . JNJ-40411813 : 500 mg single oral dose lower match placebo . Ketamine : continuous intravenous infusion 0.005 mg/kg/min 60 minute .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Confusion</mesh_term>
	<mesh_term>Perceptual Disorders</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Body mass index ( BMI ) 18 30 kg/m2 Nonsmokers Healthy basis psychiatric examination accord MINI screen Healthy basis clinical laboratory test perform screen Healthy basis physical examination , vital sign ( include stand blood pressure heart rate ) 12 lead ECG Screening Having contraindication use ketamine Significant history current psychiatric neurological illness Positive urine screen drug abuse Screening admission Positive alcohol breath test Screening admission History alcohol drug abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Activity JNJ-40411813</keyword>
	<keyword>Challenge study</keyword>
</DOC>